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The remodelling of uteroplacental arteries is a key process in the first half of human 
pregnancy. The transformation from low-flow/high-resistance to high-flow/low-resistance 
arteries that ensures sufficient blood supply to meet the requirements of the fetus, is 
caused by a loss of elasticity and vasomotor control. This remodelling is facilitated by 
perivascular invasion of extravillous trophoblast cells and infiltration of vessel walls by 
endovascular trophoblast cells. Impaired trophoblast invasion of the myometrial segments 
is therefore associated with placental hypoperfusion and may play a role in the 
pathogenesis of some cases of intrauterine growth restriction and preeclampsia. 
Preeclampsia is a multisystem disorder of pregnancy triggered by placental ischemia and 
release of placental factors causing widespread endothelial dysfunction [1]. The reasons for 
altered trophoblast invasion in preeclampsia are incompletely understood, but similarities 
between development of normal placenta and development of cancer point toward a key 
role of growth factors in normal and abnormal placentation [2]. 
MicroRNAs (miRNA) are becoming increasingly recognised as critical regulators of cellular 
function.  These short non-coding RNA species act via repression of gene targets mediated 
through binding to miRNA “seed sequences” usually, but not exclusively, located in the 
3’untranslated region. This interaction leads to a block in translation of the gene to protein 
or induction of messenger RNA degradation. As such, the expression pattern and potential 
dysregulation of individual miRNA species, or “miRNA signatures” in individual cells, tissues 
and organs are critical in understanding the role of miRNAs in health and disease. Although 
the discovery of miRNA was initially made in 1993 [3], it is only in recent years that full 
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recognition of their broad importance in cellular homeostasis as well as the potential of 
miRNAs as therapeutic entities and as biomarkers of disease has been established.  
In contrast to diseases such as those of the heart and cancer, relatively little is known about 
miRNA during pregnancy, both at the level of normal placental growth and function and in 
the pathophysiology of complications in pregnancy, including preeclampsia. This lack of data 
is a consequence of the relative lack of studies in this area, and the complications of 
addressing an exclusively human disease. In addition, there are challenges in addressing the 
discrepancy between the key pathophysiological changes that are initiated well before 20 
weeks' gestation and the clinical symptoms that are not manifest until after 20 weeks 
gestation. With preeclampsia being an exclusively human disease, clinical studies on miRNA 
expression are often restricted to placenta tissue at the time of delivery. Nevertheless, the 
available studies confirm dysregulation miRNAs that play a role in the regulation of 
trophoblast cell invasion such as miR-195 [4], miR-29b [5], and mitochondrial function such 
as miR-210 [6]. In this issue of Hypertension [7], Fu and colleagues assess, in detail, one 
particular miRNA, miR-376c and its expression and function in normal pregnancy and in 
preecampsia using a range of cellular assays, molecular manipulations and patient materials. 
MiR-376c is expressed within a region of imprinted DNA on human chromosome 14, a 
region rich in non-coding RNA species including an abundance of distinct miRNAs 
(http://www.ensembl.org/Homo_sapiens/Location/View?db=core;r=14:100505828-
102472517;region=AL132709.5). Indeed, miR-376c itself is transcribed from the miR376 
cluster pri-miRNA complex that encodes 5 separate mature miRNAs, a region recently linked 
to the development of glioma [8]. The experiments presented in this study can clearly be 
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divided into evaluation of miR-376c in clinical material, assessment of function in vitro by 
manipulation of miR-376c in relevant systems and the mechanism of action. 
The clinical sample dataset presented essentially leads to the hypothesis that 
downregulation of this miRNA is important in preeclampsia. The data demonstrate that miR-
376c is modestly upregulated during the time course of normal pregnancy through the three 
trimesters, but is downregulated in the placental tissue RNA samples of preeclamptic cases 
that have term births (but intriguingly not in those with pre-term births) compared to age-
matched controls. Importantly, plasma levels of miR-376c are lower in both pre-term and 
term samples vs controls. Cases were recruited from sites in China and Canada and, 
although not large patients numbers, the sample set shows significant differences in levels 
of miR-376c. . In Fig. 1A-D the authors present their data in box plots representing median 
values, 25% and 75% percentiles, and minimum and maximum values. Although they used 
an appropriate data presentation, it appears (Fig 1D-F) that the values are not normally 
distributed; yet, parametric statistics have been used. Further rigorous analysis using larger 
patient populations will be important, both for clarity, validation and assessment of the 
influence of geographical variation.  The authors have reported relative miR-376c levels with 
U6 as an internal control in these samples. It is well known for plasma/serum-derived 
samples that stringent controlling and normalisation is difficult. A number of strategies have 
therefore evolved, including spiking controls or normalisation using entire miRNA 
expression datasets that would be invaluable for inclusion in future studies for confirmation 
of this important finding. This is especially important in defining the utility of miR-376c, or 
indeed any other miRNA, as a biomarker of the preeclamptic condition. Nevertheless, the 
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data presented certaintly suggest that miR-376c is downregulated and that this may be 
important in the pathophysiology of preeclampsia. 
Next, the authors present a thorough and compelling series of experiments that define the 
effect of miR-376c manipulation using an immortlised cell line, stable transfectants and 
placental villous tip explants. They show that simple overexpression of miR-376c in any of 
these model systems has, in general, the overall effect of enhancing trophoblast cell growth 
and migration and conversely, downregulation of miR-376c reduces these effects on 
trophoblast cells.  Clearly, caution is required when artificially manipulating miRNA by 
overexpression or inhibition, since the resulting levels achieved can be dramatically affected 
and beyond the levels altered in the disease under study. Although lacking details such as 
Cy3-labelled visualisation of transfection percentages and locales in the explant model, 
these studies support the concept that downregulation of miR-376c hinder trophoblast 
proliferation and migration, supporting the hypothesis that originated from assessment of 
clinical material.  
An important component of this study is a detailed account of the proposed mechanism of 
action of miR376c in the setting of trophoblast function. The authors focus on the 
transforming growth factor- and Nodal pathway. Using reporter assays, they show that 
both activin-like kinase (ALK)5 and ALK7 are direct, validated targets of miR-376c. They 
further show that manipulation of miR-376c leads to the reciprocal alteration in ALK5 and 
ALK7 at the protein level. Moreover, siRNA to ALK5 (but not ALK7) mimics the effect of 
miR376c overexpression and the effects of miR-376c can be overridden by plasmid-
mediated overexpression of ALK5 or ALK7. Combining siRNAs or plasmid systems in a single 
experiment to manipulate both ALK5 and ALK7 simultaneously may be a useful strategy to 
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further refine these experiments. Furthermore, miR-376c has many other putative gene 
targets and whilst it is beyond the scope of the current paper, the impact of miR-376c on 
other targets expressed in trophoblasts would be important to assess globally the 
transcriptional influence of this miRNA in trophoblasts. Mechanistically, the authors conduct 
the necessary experiments to show that miR-376c overexpression acts to repress both TGF-
- and Nodal-induced signalling (blocked pSMAD2/3 activation) and expression of pathway 
responsive genes (e.g. p21). Thus, the study provides compelling data to suggest that miR-
376c plays an important role in normal pregnancy through regulation of ALK5 and ALK7 
activation mediated by TGF-B and Nodal, respectively and that downregulation in 
preeclampsia combined with elevated TGF- and Nodal levels leads to enhanced activation 
of ALK5/ALK7, in turn resulting in reduced trophoblast growth and invasion and ultimately, 
preeclampsia. 
In any complex system, interplay between different cell types and their enviornmental cues 
impact on disease progression. Within any given cell type, many miRNA are expressed and 
their levels are governed by processes including transcriptional regulation, miRNA 
processing and activity. In addition, the secretion of miRNA from cells has the capacity to 
impact the function of other cells locally should the miRNA be taken up. As suggested, this 
may certainly impact upon similar signalling systems in alternate cell types, such as 
endothelium or smooth muscle. It is very clear that the effect of miR-376c on trophoblast 
cell function is potent, and is focused on signalling mediated by TGF- and Nodal. What 
about other miRNAs? It has been established that miRNAs can work alone or in concert with 
other miRNAs to affect the transcriptome in healthy cells and in the progression of disease 
[9]. With respect to the latter, this may be via multiple mechanisms, including different 
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miRNAs acting upon different biological pathways relevant to the pathogenesis of a 
particular disease, or different miRNAs acting together upon a single biological pathway or 
system. In support of the latter, the same group that published this study also very recently 
reported the role  of miR-378a-5p using a very similar series of samples and experiments 
[10]. Essentially, they showed that miR-378-5p was also downregulated in preeclamptic 
placental tissue compared to controls and that the function and mechanism was to target 
the 3’UTR of Nodal to repress Nodal-induced repression of trophoblast growth and invasion. 
Also, Zhu et al. [11] found dysregulation of 34 miRNAs in placentas from women with 
preeclampsia; one of the differentially regulated miRNAs was miR195. More recently, Bai et 
al. [4] confirmed downregulation of miR-195 and demonstrated that ActRIIA, the type II 
receptor for ActivinA and Nodal, is a target of miR-195/mir195. Thus, there is likely to be 
complex interplay and regulation of different miRNAs species that impact on pathways 
relevant to trophoblast function, and/or endothelial function and the pathogenesis of 
preeclampsia. A systems approach to address this would clearly be warranted. 
Preeclampsia affects between 2 and 7 percent of pregnant women, and depsite years of 
ongoing research the etiology of the disorder remains incompletely understood. One of the 
most consistently described features of the condition are reduced levels of angiogenic 
factors such as VEGF compared to normal pregnancy, in part due to presence of a soluble 
form of the VEGF receptor (sFlt-1), and possibly triggered by placental hypoxia. Another 
important factor associated with the pathogenesis of preeclampsia is soluble endoglin, 
which acts as a TGF-beta antagonist. The finding by Fu and colleagues [7] that TGF-beta 
signalling can also be altered through miR-376c and its actions on Nodal is in line with the 
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overall concept of preeclampsia being a disorder if impaired vasculogenesis and provides an 
explanation at the level of gene transcription. 
 
In order to establish miR-376c as a predictive or diagnostic biomarker of preeclampsia, the 
study by Fu and colleagues [7] requires confirmation in independent and larger cohorts. 
Already at this stage, however, it provides a better understanding of the processes leading 
to impaired trophoblast invasion in preeclampsia. Even if the study by Fu et al. elegantly 
demonstrated dysregulation of miR-376c in plasma samples from early pregnancy it remains 
unclear if miR-376c expression was downregulated prior topregnancy and if it remains 
downregulated in vascular tissues after pregnancy. In the light of the key role of TGF-β 
signalling in a wide range of conditions including cardiovascular and renal diseases [12] and 
the increased cardiovascular risk of women with a history of preeclampsia [13] it will be 
important to study if dysregulation of TGF-β targeting miRNAsprovides a link between 
preeclampsia and other vascular diseases. 
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